The Eli Lilly and Genmab-backed RNA drug developer is now valued at nearly $1.5bn following a decision to refocus on a coronavirus vaccine.

German government-owned development bank KfW agreed yesterday to invest €300m ($339m) in CureVac, the Germany-based RNA therapy developer backed by pharmaceutical firm Eli Lilly. CureVac is working on messenger RNA (mRNA)-based drugs but its technology could also influence development of a vaccine for Covid-19. It has two drug candidates in phase 1 clinical trials, each…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.